Table 4.

Change in serum chemistry between baseline and each time point (30 days and 90 days)

Clinical pathology parameter	Δ (Baseline to 30 days)			Δ (Baseline to 90 days)
	Treatment	Control	p-value	Treatment	Control	p-value
Aspartate aminotransferaces test (AST)	26.8 ± 38.41	2.0 ± 5.29	0.323	2.8 ± 11.5	16.33 ± 7.51	0.123
Alanine aminotransferase test (ALT)	15.6 ± 14.3	13.0 ± 9.0	0.790	20.4 ± 14.01	26.33 ± 14.74	0.589
Alkaline phosphatase test (ALP)	− 2.0 ± 49.89	8.33 ± 25.06	0.796	− 36.8 ± 54.36	− 45.7 ± 36.02	0.813
Gamma-glutamyl transferase (GGT)	0.40 ± 7.29	4.53 ± 4.12	0.412	− 3.64 ± 5.87	− 0.74 ± 2.07	0.451
Creatinine	0.02 ± 0.18	0.03 ± 0.12	0.913	0.16 ± 0.21	0.23 ± 0.31	0.696
Albumin	− 0.08 ± 0.16	− 0.1 ± 0.1	0.857	− 0.06 ± 0.3	0 ± 0.26	0.784
Albumin globulin (A/G) ratio	0.08 ± 0.13	− 0.03 ± 0.12	0.263	− 0.22 ± 0.19	− 0.43 ± 0.12	0.138
Amylase (VAMY)	457 ± 613.95	342 ± 462.52	0.791	508 ± 509	675 ± 357.79	0.640
Lipase (LIPASE)	9.0 ± 36.24	− 3.0 ± 3.61	0.600	7.4 ± 9.29	10 ± 13.89	0.758
Glucose	− 21.0 ± 27.63	− 23.67 ± 22.37	0.893	− 14.0 ± 18.96	− 8.67 ± 22.37	0.730
Cholesterol	− 2.8 ± 14.10	− 11.00 ± 13.86	0.454	− 4.2 ± 9.83	2.0 ± 13.86	0.482
Tryglycerides	12.42 ± 9.56	23.73 ± 25.97	0.395	− 3.94 ± 4.45	− 4.13 ± 5.63	0.958

One-way analysis of variance (ANOVA) was used to examine differences in serum chemistry between treatment and control groups at each end points

A p value greater than 0.05 was considered insignificant